Introduction
Materials and methods
Experimental design
Determination of cefepime concentrations in the plasma
PK parameters
Clinical and laboratory parameters, and PK/PD analyses
Reason for ICU admission | Underlying disease | SAPS II score | Weight (Kg) | ClCr | Presumed pathogens | MIC (mg/l) |
---|---|---|---|---|---|---|
Cardiovascular surgery 1 | Coronary artery disease | 38 | 75 | 17.8 | ||
Multiple trauma | Bipolar disorder | 33 | 75 | 139.3 |
E. coli
| 0.024 |
Thoracic surgery 2 | Non-specific interstitial pneumonia | 33 | 85 | 126.6 | ||
Abdominal surgery 3 | Abdominal aortic aneurysms | 26 | 75 | 51 | ||
Multiple trauma | Chronic obstructive pulmonary disease | 23 | 86 | 63.4 |
S. aureus
| 2 |
Abdominal surgery | Abdominal aortic aneurysms | 32 | 85 | 32.9 | ||
Cardiovascular surgery | Aortic stenosis | 47 | 63 | 62.2 | ||
Acute respiratory failure 4 | Obesity stage II | 24 | 120 | 135.5 |
S. pneumoniae
| 0.75 |
Neurosurgery | Cerebral arterio-venous malformation | 50 | 53 | 166.9 |
E. coli
| 0.04 |
Cardiovascular surgery | Myeloproliferative disorder | 52 | 65 | 79.6 |
S. pneumoniae
| 0.047 |
Multiple trauma | None | 42 | 70 | 133.5 |
P. aeruginosa
| 4 |
Cardiovascular surgery | Aortic bicuspidy | 9 | 68 | 101.9 | ||
Acute respiratory failure 1 | Coronary artery disease | 51 | 60 | 12 | ||
Neurosurgery | None | 23 | 40 | 161 |
P. aeruginosa
| 4 |
Multiple trauma | Diabetes mellitus | 22 | 58 | 92.1 | ||
Cardiovascular surgery | Coronary artery disease | 24 | 78 | 59.8 | ||
Acute respiratory failure 4 | Myeloproliferative disorder | 69 | 52 | 95.5 |
S. pneumoniae
| 1 |
Cardiovascular surgery | Coronary artery disease | 33 | 47 | 115.1 | ||
Multiple trauma | None | 24 | 62 | 142.1 | ||
Ear-nose and throat surgery | Pharynx carcinoma | 43 | 60 | 87.7 | ||
Neurosurgery | High blood pressure | 58 | 100 | 121.8 |
H. influenzae
| 1 |
Evaluation endpoints
Results
Patient characteristics
Cefepime PK profiles
Parameters and time of calculation | Mean reported values ± SD | |||
---|---|---|---|---|
Present study | Barbhaiya et al. 3[45] | Sampol et al.4[50] | Bonapace et al.4[44] | |
First dose (17 patients) | ||||
T1/2β (h) | 4.03 ± 3.19 | NS | 2.45 ± 0.56 | 2.8 ± 0.6 |
CMax (mg/l) 1 | 105 ± 22 | 132 ± 21 | NS | 102 ± 15 5 |
CMin (mg/l)1 | 7.6 ± 12 | NS | NS | NS |
AUC (mg.h/liter) | 370 ± 360 | 268 ± 27 | 217 ± 34 | 224 ± 59 |
MRT (h) | 5.1 ± 4.64 | 2.56 ± 0.31 | NS | NS |
Clearance (liter/h.kg) 1,2 | 0.130 ± 0.077 | NS | 0.152 ± 0.025 | 0.1 ± 0.03 |
Vβ (liter/kg) | 0.513 ± 0.180 | NS | NS | NS |
VSS (liter/kg) | 0.413 ± 0.118 | NS | 0.36 ± 0.1 | 0.43 ± 0.1 |
Steady state (11 patients) | ||||
T1/2β (h) | 4.33 ± 4.32 | Not available | 2.62 ± 0.53 | Not available |
CMax (mg/l) 1 | 97 ± 8 | NS | ||
CMin (mg/l)1 | 2.68 ± 3.06 | NS | ||
AUC (mg.h/liter)1 | 226 ± 107 | 262 ± 57 | ||
MRT (h) | 5.3 ± 5.9 | NS | ||
Clearance (liter/h.kg) | 0.131 ± 0.084 | 0.133 ± 0.029 | ||
Vβ (liter/kg) | 0.513 ± 0.180 | NS | ||
VSS (liter/kg) | 0.413 ± 0.118 | 0.35 ± 0.1 |
Factors influencing PK profiles
Clinical and laboratory parameters | Pharmacokinetic parameters 1,2(number of data points) | |||||
---|---|---|---|---|---|---|
K
β
|
T
1/2β
| MRTiv | CLCEF |
V
β
|
V
SS
| |
Weight
| 0.08 | -0.05 | -0.04 | -0.34 | -0.42** | -0.47** |
(28) | (28) | (28) | (28) | (28) | (28) | |
Age
| -0.65** | 0.58* | 0.61* | -0.75** |
-0.50**
| -0.34 |
(28) | (28) | (28) | (28) |
(28)
| (28) | |
Proteins
| 0.52* | -0.27 | -0.28 | 0.24 | -0.13 | -0.29 |
(26) | (26) | (26) | (26) | (26) | (26) | |
Albumin
|
0.63*
| -0.31 | -0.32 | 0.21 | -0.27 | -0.43** |
(26)
| (26) | (26) | (26) | (26) | (26) | |
Hemoglobin
| 0.07 | 0.06 | 0.07 | -0.42** |
-0.58**
|
-0.59**
|
(28) | (28) | (28) | (28) |
(28)
|
(28)
| |
Na
+
| -0.11 | 0.01 | -0.01 | 0.17 | 0.38 | 0.38 |
(28) | (28) | (28) | (28) | (28) | (28) | |
Creatinine
| -0.78** | 0.91* | 0.91* | -0.69** | -0.31 | -0.19 |
(27) | (27) | (27) | (27) | (27) | (27) | |
CL
Cr
|
0.79*
|
-0.81**
|
-0.82**
|
0.88*
| 0.51* | 0.35 |
(27)
|
(27)
|
(27)
|
(27)
| (27) | (27) | |
pCO
2
| 0.28 | -0.41 | -0.42** | 0.03 | -0.14 | -0.20 |
(23) | (23) | (23) | (23) | (23) | (23) | |
HCO
3
| 0.33 | -0.42** | -0.41 | -0.05 | -0.27 | -0.33 |
(23) | (23) | (23) | (23) | (23) | (23) | |
Cefepime dose (mg/kg)
| 0.19 | -0.17 | -0.17 |
0.57*
| 0.51* | 0.53* |
(28) | (28) | (28) |
(28)
| (28) | (28) |
Side effects
Pharmacodynamic profiles and clinical outcome
1st dose (N patients = 15) | steady state (N patients = 9) | |||
---|---|---|---|---|
T>MIC | ≤4 mg/ml 1 | 8 mg/ml 1 | ≤4 mg/ml 1 | 8 mg/ml 1 |
>0.3 (3:36 h) | 100% | 100% | 100% | 100% |
>0.4 (4:48 h) | 100% | 87% | 100% | 67% |
>0.5 (6:00 h) | 100% | 67% | 100% | 44% |
>0.6 (7:12 h) | 67% | 47% | 67% | 22% |
>0.7 (8:24 h) | 53% | 40% | 33% | 22% |
Discussion
Conclusions
Key messages
-
2 g of cefepime every 12 h was safe and appropriate for patients with CLCr ≥50 ml/min pathogens with cefepime MICs ≤4 mg/l.
-
However, this dosage was too low up to 50% of more of patients infected with microbes with greater cefepime MICs (≥8 mg/l).
-
Moreover, cefepime accumulation and neurological toxicity (non-convulsive epilepsy) occurred in two patients with CLCr <50 ml/minute, in spite of drug dosage adjustment.
-
Monitoring of cefepime plasma levels is warranted in patients with CLCr <50 ml/minute and infection due to pathogens with cefepime MICs ≥8 mg/l.